SCHEMBL2354022

SCHEMBL2354022

O=C(Nc1ccc(N2CCCCC2)cc1)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 17/20 1.00
NPC1 O15118 15/20 1.00
SMN1; SMN2 Q16637 13/20 1.00
MAPT P10636 13/20 1.00
TP53 P04637 4/20 1.00
PKM P14618 3/20 1.00
NFKB1 P19838 1/20 1.00
NFKB2 Q00653 1/20 1.00
RELA Q04206 1/20 1.00
MAPK1 P28482 3/20 0.74
HTT P42858 2/20 0.74
ALOX15 P16050 1/20 0.74
KMT2A Q03164 5/20 0.71
MEN1 O00255 3/20 0.71
MCL1 Q07820 3/20 0.71
L3MBTL1 Q9Y468 3/20 0.71
LMNA P02545 3/20 0.71
KDM4E B2RXH2 2/20 0.71
USP2 O75604 2/20 0.71
ALDH1A1 P00352 5/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4251987 0.92 RAB9A (0.85) RAB9ANPC1SMN1; SMN2MAPTTP53
SCHEMBL28090799 0.90 RAB9A (0.83) RAB9ANPC1SMN1; SMN2MAPTTP53
SCHEMBL30828596 0.88 RAB9A (0.78) RAB9ANPC1SMN1; SMN2MAPTTP53
SCHEMBL8769429 0.88 RAB9A (0.78) RAB9ANPC1SMN1; SMN2MAPTTP53
SCHEMBL2565238 0.86 HDAC8 (0.76) RAB9ANPC1SMN1; SMN2MAPTTP53
SCHEMBL8769840 0.86 RAB9A (0.78) RAB9ANPC1SMN1; SMN2MAPTTP53
SCHEMBL8770201 0.86 RAB9A (0.78) RAB9ANPC1SMN1; SMN2MAPTTP53
SCHEMBL3142490 0.85 RAB9A (1.00) RAB9ANPC1SMN1; SMN2MAPTTP53
SCHEMBL18470910 0.85 RAB9A (1.00) RAB9ANPC1SMN1; SMN2MAPTTP53
SCHEMBL532678 0.85 MAPT (0.74) RAB9ANPC1SMN1; SMN2MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8729081-B2 Compositions and methods for treating alcohol use disorders, pain and other diseases VM DISCOVERY INC. (US) 2014-05-20 US disclosed
US-20110301149-A1 COMPOSITIONS AND METHODS FOR TREATING ALCOHOL USE DISORDERS, PAIN AND OTHER DISEASES VM DISCOVERY INC. (US) 2011-12-08 US disclosed
EP-2356109-A2 COMPOSITIONS AND METHODS FOR TREATING ALCOHOL USE DISORDERS, PAIN AND OTHER DISEASES VM Discovery, Inc. (US) 2011-08-17 EP disclosed
WO-2010042925-A2 COMPOSITIONS AND METHODS FOR TREATING ALCOHOL USE DISORDERS, PAIN AND OTHER DISEASES VM DISCOVERY INC. (US) 2010-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301149-A1 COMPOSITIONS AND METHODS FOR TREATING ALCOHOL USE DISORDERS, PAIN AND OTHER DISEASES PRKCH, PRKCG, PRKCQ RAB9A 2196/4885NPC1 1647/4885SMN1; SMN2 2857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.